• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
ASAM Member Survey Results
 

ASAM Member Survey Results

on

  • 627 views

 

Statistics

Views

Total Views
627
Views on SlideShare
547
Embed Views
80

Actions

Likes
0
Downloads
1
Comments
0

1 Embed 80

http://www.asam.org 80

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    ASAM Member Survey Results ASAM Member Survey Results Presentation Transcript

    •  91.7% of respondents (343 out of 374) have a DEA waiver to prescribe buprenorphine for at least 30 patients  73.3% are waivered to treat 100 patients  43.8 % of respondents indicated they have demand for buprenorphine treatment that exceeds the 100 patient limit
    • 6.3% 30.4% 10.1% 7.4% 15.5% 30.4% 0% 5% 10% 15% 20% 25% 30% 35% More than 100 81-100 61-80 41-60 21-40 Fewer than 20 The Number Patients per Month for whom Respondents Currently Prescribe Buprenorphine for theTreatment of Opioid Dependence
    • 2.8% 62.8% 8.9% 10.0% 23.1% 18.3% 0% 10% 20% 30% 40% 50% 60% 70% Other* None of the above All of the above CertifiedAddictions Registered Nurses (CARN) Nurse Practitioners Physicians'Assistants Percent of Respondents Who FeelThis Group Should be Allowed to Apply for and Obtain a Waiver to Prescribe Buprenorphine for theTreatment of Opioid Addiction *Other comments include: lifting 100 patient limit for ABAM certified physicians, requiring supervision for above groups to prescribe.
    •  19.8% of respondents order or prescribe medications for the treatment of opioid dependence in/from a federally-approved OTP  79.5% of these order methadone  57.3% order or prescribe buprenorphine  Most respondents indicated that states impose requirements – such as time in treatment or compliance with diversion control programs – in order for patients to gain take-home privileges for buprenorphine
    •  38.7% of respondents prescribe extended release naltrexone for opioid dependent patients  The vast majority of patients (62.2%) receive their injection in a private office setting
    • 15.0% 8.3% 10.5% 66.2% 0% 10% 20% 30% 40% 50% 60% 70% More than 15 11-15 6-10 1-5 The Number of Patients for whom Respondents Currently Prescribe Extended Release Naltrexone
    •  55.4% of respondents prescribe oral naltrexone for opioid dependent patients